Inactive Instrument

Highlights Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting	05-09	CI
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	02-20	MT
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.	02-19	CI
Freeline shareholders approve Syncona acquisition	02-12	AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	02-12	MT
Syncona says Freeline trial for Gaucher disease treatment positive	01-19	AN
Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2023	12-01	CI
Syncona agrees to buyout deal with Freeline Therapeutics	11-22	AN
Syncona to Take Over Freeline Therapeutics	11-22	MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million	11-22	MT
Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate	25/10/23	CI
Syncona Submits Takeover Bid for Freeline Therapeutics	18/10/23	MT
Syncona announces takeover offer for Freeline Therapeutics	18/10/23	AN
SYNCONA LIMITED - PROPOSAL TO ACQUIRE FREELINE THERAPEUTICS…	18/10/23	RE
Syncona Seeks to Buy Remaining Shares of Freeline Therapeutics	18/10/23	CI
Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc for	17/10/23	CI
Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease	04/10/23	CI
Freeline Therapeutics Holdings plc Reports Earnings Results for the Half Year Ended June 30, 2023	15/08/23	CI
Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease	26/06/23	CI
Syncona investee Freeline swings to first-quarter profit	30/05/23	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Highlights

Filters